TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05935839

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle Brachial Index
Description: Dual measurement of ABI index before and after physical exercise.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle Brachial Index
Description: Dual measurement of ABI index before and after physical exercise.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle Brachial Index
Description: Dual measurement of ABI index before and after physical exercise.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropathy Disability Score
Description: Single measurement of the NSS

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropathy Disability Score
Description: Single measurement of the NSS

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropathy Disability Score
Description: Single measurement of the NSS
Study: NCT06372288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS using Intermittent theta burst stimulation (iTBS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Participants will not receive intermittent theta burst stimulation during the sham-TMS sessions
Study: NCT00605774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
Study: NCT05828251

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vitrectomy (Sequential phakoemulsification and vitrectomy)
Description: Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy (Sequential phakoemulsification and vitrectomy)
Description: Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined phako-vitrectomy
Description: Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phako (Sequential phakoemulsification and vitrectomy)
Description: Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phako (Sequential phakoemulsification and vitrectomy)
Description: Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
Study: NCT04781634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 and CD22 targeted prime CAR-T cells
Description: A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
Study: NCT06062966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg SC daily will be administered to sujects on chronic inotrope treatment who are not candidates for transplantation or left ventricular assist device (LVAD).
Study: NCT05766137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: Socket preservation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: Socket preservation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation
Description: Socket preservation
Study: NCT06075407

Intervention type: DEVICE
Intervention: Assessment of fluid responsiveness by electrical cardiometry
Description: Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotropic, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3).~Transthoracic echocardiography (TTE) measurements will be performed equipped with echo probe. SV of the left ventricle will be calculated using LVOT diameter (D) just below the aortic valve from parasternal long-axis view and VTI measured in LVOT from apical 5 chamber view (by pulsed wave Doppler).

Intervention type: DEVICE
Intervention: Assessment of fluid responsiveness by electrical cardiometry
Description: Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotropic, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3).~Transthoracic echocardiography (TTE) measurements will be performed equipped with echo probe. SV of the left ventricle will be calculated using LVOT diameter (D) just below the aortic valve from parasternal long-axis view and VTI measured in LVOT from apical 5 chamber view (by pulsed wave Doppler).
Study: NCT05262296

Intervention type: PROCEDURE
Intervention: Laparoscopic Surgeon
Description: Laparoscopic Arm This cohort of participants will have their procedure completed by a human surgeon.

Intervention type: PROCEDURE
Intervention: Robotic Arm
Description: This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
Study: NCT05501470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CapScan®
Description: The only non-standard sample collection instrument is the CapScan® device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples.
Study: NCT05772533

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG block
Description: Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered.
Study: NCT04766242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spiritual healing
Description: The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
Study: NCT05728346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers
Description: stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
Study: NCT04922359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
Study: NCT05584306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 610 30mg group
Description: 610 30mg subcutaneous (SC) Q4W，8 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 610 100mg group
Description: 610 100mg subcutaneous (SC) Q4W，8 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 610 300mg group
Description: 610 300mg subcutaneous (SC) Q4W，8 times

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 30mg group
Description: placebo subcutaneous (SC) Q4W，8 times

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 100mg group
Description: placebo subcutaneous (SC) Q4W，8 times

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300mg group
Description: placebo subcutaneous (SC) Q4W，8 times
Study: NCT06411054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Description: After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 4-12mA, and pulse width of 300µS will be delivered continually for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).
Study: NCT05149391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20-directed Chimeric Antigen Receptor T Cells
Description: Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
Study: NCT06106347

Intervention type: DEVICE
Intervention: mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)
Description: physiological macular function
Study: NCT05562258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Coaching and Patient Education
Description: This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to a coach and patients will have access to weekly educational material.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Education and Patient Coaching
Description: This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to weekly educational material and patients will have access to a coach.
Study: NCT06411054

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acu-TENS
Description: After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair.~In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current. The pads will be stuck on the acupoints for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).
Study: NCT05836402

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet intervention
Description: Patients will receive a study kit. The kit will contain the following:~* Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~* A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB (Package insert)
Study: NCT05297097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trulacta breastmilk supplement
Description: one supplement daily
Study: NCT05520411

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HUM Flatter Me
Description: Proprietary Enzyme Blend: Protease 3.0 Protease 4.5 Protease 6.0 Neutral Bacterial Protease Peptidase Bromelain Papain Lipase Amylase Glucoamylase Alpha-galactosidase Invertase Diastase Hemicellulase + Cellulase Beta-Glucanase Phytase Lactase Ginger Root Fennel Seed Peppermint Leaf
Study: NCT05726994

Intervention type: BIOLOGICAL
Intervention: exhaled breath collection
Description: Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.

Intervention type: OTHER
Intervention: Data collection
Description: Clinical data will be collected in order to seek correlations with the exhaled breath profile.
Study: NCT04840329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: One-time educational session about menstrual health and endometriosis
Study: NCT05025878

Intervention type: DIETARY_SUPPLEMENT
Intervention: [U-13C]Glucose
Description: Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.
Study: NCT06142617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, pemetrexed, platinum
Description: Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be the sequential treatment strategy at progression until resistance develops.
Study: NCT04600934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Shockwave Medical, Inc. Peripheral Lithoplasty® System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain old balloon angioplasty
Description: POBA
Study: NCT06389851

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Case Group - Tomato-free diet
Description: Nutritional intervention without tomatoes and sauce

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Case group - Diet enriched with tomatoes
Description: Nutritional intervention enriched with tomatoes and souce
Study: NCT06230107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
Study: NCT05600101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care.Coach
Description: Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates.
Study: NCT06063382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exam
Description: Academic exam based on the Brazilian National High School Exam (ENEM).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exam
Description: Academic exam based on the Brazilian National High School Exam (ENEM).
Study: NCT06244862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
Study: NCT06063382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exam
Description: Academic exam based on the Brazilian National High School Exam (ENEM).
Study: NCT05591326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-PRF application procedure
Description: Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
Study: NCT06363565

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation of compound nutrients
Description: Folic acid, vitamin B6, vitamin B12, and betaine per day orally for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: The placebo is an excipient and the color, flavor, shape, taste, and weight are same with the tablet of supplement.
Study: NCT05228392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music
Description: listening to lullaby or other music types

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music
Description: listening to lullaby or other music types
Study: NCT05282719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax combined with azacitidine
Description: On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
Study: NCT05764187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthodontic fixed appliance therapy
Description: Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic fixed appliance therapy
Description: Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets
Study: NCT06083350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast beta-glucan
Description: Produced by Angel Yeast Co., LTD

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Produced by Angel Yeast Co., LTD
Study: NCT06146946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dissection of the No.253 lymph node
Description: The range of the No.253 lymph node is as follows: medially, it extends from the root of the inferior mesenteric artery to the starting section of the left colonic artery; caudally, from the starting point of the left colonic artery to the intersection with the inferior mesenteric vein; laterally, it is bordered by the outer margin of the inferior mesenteric vein; and cranially, from the horizontal section of the duodenum to the beginning of the jejunum. In the controlled group, the surgery is performed with dissection of the No.253 lymph node.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omitting the dissection of the No.253 lymph node
Description: In the experimental group, the surgery is performed without dissection of the No.253 lymph node.
Study: NCT05866861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUG252
Description: CUG252 will be administered by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection.
Study: NCT04694677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: women receiving tranexamic acid
Description: women receiving tranexamic acid during myomectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: women receiving misoprostol
Description: women receiving misoprostol in myomectomy
Study: NCT05607342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osanetant
Description: To evaluate the effect of Osanetant on the testosterone levels.
Study: NCT04837807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Hydration PF
Description: This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
Study: NCT05823766

Intervention type: BEHAVIORAL
Intervention: In-Person Outcome Assessment
Description: Assessments will be administered to evaluate participant outcome status

Intervention type: BEHAVIORAL
Intervention: In-Person Outcome Assessment
Description: Assessments will be administered to evaluate participant outcome status

Intervention type: BEHAVIORAL
Intervention: In-Person Outcome Assessment
Description: Assessments will be administered to evaluate participant outcome status

Intervention type: PROCEDURE
Intervention: 3T Magnetic Resonance Imaging (MRI)
Description: Participants will be asked to complete a 3T MRI
Study: NCT04825639

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT05823766

Intervention type: PROCEDURE
Intervention: 3T Magnetic Resonance Imaging (MRI)
Description: Participants will be asked to complete a 3T MRI

Intervention type: PROCEDURE
Intervention: 3T Magnetic Resonance Imaging (MRI)
Description: Participants will be asked to complete a 3T MRI

Intervention type: BEHAVIORAL
Intervention: Clinical Visit
Description: Patients who screen positive for PTE will have an in-depth clinical visit

Intervention type: BEHAVIORAL
Intervention: Clinical Visit
Description: Patients who screen positive for PTE will have an in-depth clinical visit